Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Guiding Management of Bethesda V Thyroid Nodules: The Role of Molecular Testing.

Clinical endocrinology - 1 Jan 2026

Tessler Idit, Morand Grégoire B, Gecel Nir A, Dotan Arad, Yamin Tzahi, Alon Eran E, Payne Richard J, Avior Galit

Abstract excerpt

OBJECTIVE: The 2023 Bethesda System update introduced molecular testing as a management option for Bethesda V cytology nodules, aiming to guide surgical decision-making. This study investigates the correlation between molecular profiling and malignancy aggressiveness. DESIGN: We conducted a retrospective multicenter study involving patients with Bethesda V cytology and confirmed malignant pathology who underwent...

Read the complete abstract on PubMed

Topics

Humans
Thyroid Nodule
Female
Male
Retrospective Studies
Middle Aged
Adult

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Aged

Thyroid Neoplasms

Mutation

Biopsy, Fine-Needle

Source

Open in PubMed Open full text

Identifiers

PMID: 40964868
DOI: 10.1111/cen.70032
PMCID: PMC12669814

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Guiding Management of Bethesda V Thyroid Nodules: The Role of Molecular Testing.PMID 40964868Read ↗

Molecular Profiling for Bethesda III to VI Nodules: Results of a Multicenter International Retrospective Study.Semantic proximity Read ↗

Preoperative molecular testing in thyroid nodules with Bethesda VI cytology: Clinical experience and review of the literature.Semantic proximity Read ↗

The 2023 Bethesda System Predicts Aggressive Features and Histologic Subtype in Thyroid CancerSemantic proximity Read ↗

The actual and future role of molecular tests in thyroid pathology.Semantic proximity Read ↗

Association of Bethesda category and molecular mutation in patients undergoing thyroidectomySemantic proximity Read ↗

Molecular Profiling of 50 734 Bethesda III-VI Thyroid Nodules by ThyroSeq v3: Implications for Personalized Management.Semantic proximity Read ↗

Clinical utility of a microRNA classifier in cytologically indeterminate thyroid nodules with RAS mutations: A multi-institutional study.Semantic proximity Read ↗

Current State of Molecular Cytology in Thyroid Nodules: Platforms and their Diagnostic and Theranostic UtilitySemantic proximity Read ↗

Update on Molecular Diagnostics in Thyroid Pathology: A ReviewSemantic proximity Read ↗

BRAFV600E genetic testing should be recommended for Bethesda III or V thyroid nodules based on fine-needle aspiration.Semantic proximity Read ↗

Clinical Implications and Application of Molecular Testing in the Diagnosis and Management of Thyroid Nodules in the Chinese Population.Semantic proximity Read ↗

BRAF V600E genetic testing should be recommended for Bethesda III or V thyroid nodules based on fine-needle aspirationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.